Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Loses Tamsulosin Launch Opportunity To Impax; Analysts Raise Doubts About Nexium, Lipitor

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - It's been a tricky and awkward situation for Ranbaxy since it admitted at the last minute to losing a big opportunity of launching the first generic version of prostate enlargement drug Flomax (tamsulosin) in the United States. On March 2, Impax launched the generic variant of the nearly $2 billion blockbuster drug as part of an October 2009 patent settlement inked with Boehringer Ingelheim

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts